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Congenital Adrenal Hypoplasia and 
Isolated Gonadotropin Deficiency 
Gad B. Kletter, Jerome L. Gorski, and Robert P. Kelch 
Congenital adrenal hypoplasia with gonadotropin deficiency is a rare 
X-linked recessive disorder that usually manifests with symptoms of 
adrenal insuficiency early in infancy. Adequate replacement therapy 
with glucocorticoids, mineralocorticoids, and salt has resulted in an 
increased survival. Slow growth and failure to undergo sexual 
maturation during the adolescent years usually ensues, secondary to 
hypogonadotropic hypogonadism. The X-linked congenital adrenal 
hypoplasia locus has been mapped to region Xp21.3-~21.2. Interstitial 
deletions of the X chromosome overlapping this region have been 
observed to cause complex clinical problems, with adrenal hypoplasia 
as a prominent component. Within a family segregating the disease, 
there is a 50% risk of having an affected male and a 50% risk of having 
a carrier female; considerations of genetic heterogeneity, possible 
chromosomal abnormalities, and prenatal diagnostic studies warrant 
medical genetic evaluations. The following case presentations illustrate 
the clinical spectrum of this condition. (Trends Endocrinol Metab 199 1; 
2:123-128) 
?? Case Presentation 1 
A &week-old infant was admitted to a 
local hospital because of weight loss and 
severe failure to thrive. Gestation and 
delivery were normal: birth weight was 
4600 g. After receiving intravenous (i.v.) 
hydration he recovered and did well until 
-3 years of age, when he began to require 
frequent hospitalizations for recurrent 
vomiting, hyperkalemic, and hypo- 
natremic dehydration, lethargy, and weak- 
ness. The diagnosis of primary adrenal 
insufficiency was made and replacement 
therapy with hydrocortisone succinate 
and 9-a-fluorohydrocortisone was begun. 
Subsequently, he was hospitalized sev- 
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era1 times because of seizures and unre- 
rig/L (normal, < 200 ng/L). Primary adre- 
sponsiveness associated with hypoglyce- 
nal insufficiency was diagnosed, and 
mia and hyponatremia. Two brothers 
therapy with mineralo- and glucocorti- 
coids was initiated. Evaluation of a 
had died suddenly at the ages of 13 possible autoimmune endocrinopathy in- 
months and 13 days, respectively. A cluded determination of all of the follow- 
maternal grandmother had two brothers ing antibody titers, all of which were 
who died in early childhood, and a sister undetectable: antiadrenal, antiislet cell, 
of that grandmother had two sons who antimitochondrial, anti-smooth-muscle, 
died in early childhood from “hypo- antiparietal cell, antithyroglobulin, and 
natremic dehydration.” antimicrosomal. Seven years later, fail- 
At age 16, when he initially came to ure to develop secondary sex characteris- 
our institution, he was a thin, short boy tics prompted further evaluation. At 15’12 
with a eunuchoid body habitus. Physical years of age, his external genitalia 
examination revealed a scant amount of showed no pubertal changes: there was a 
pubic hair and minimal scrotal thinning. scant amount of pubic hair, and the 
Pituitary gonadotropin responses to syn- phallus and testes were prepubertal in 
thetic GnRH (2.5 pg/kg) were low [mean size. Bone age was 13 years; serum 
basal luteinizing hormone (LH) 3.9 IU/L, gonadotropin concentrations were some- 
maximal increment 2.9 IU/L; and mean what low (FSH 4.2 and LH 1.6 IWL); 
basal follicle-stimulating hormone (FSH) serum testosterone was undetectable. 
1.9 IU/L, maximal increment 1.6 WL]. The diagnosis of hypogonadotropic hy- 
Serum testosterone was 2.1 nmol/L, and pogonadism was suspected, and he was 
bone age was 13 years. admitted for evaluation of gonadotropin 
ENDOCRINE ROUNDS 
He was admitted to the Clinical Re- 
search Center for detailed evaluation of 
gonadotropin secretion and responses to 
pulsatile administration of synthetic 
GnRH (0.025 pg/kg per dose every 2 h for 
5 days). His response to synthetic GnRH 
was minimal (Figure 1); serum LH a 
subunit did not increase (data not shown). 
He was started on therapy with depot 
testosterone enanthate, and full mas- 
culinization ensued. 
?? Case Presentation 2 
A 7-year-old boy was referred because of 
vomiting and increasing fatigue over the 
past 3 months. He had not experienced 
weight loss or diarrhea. Family history 
was noncontributory. On admission, his 
weight was 30.2 kg (90th percentile for 
age) and his height was 130 cm (80th 
percentile). Physical examination revealed 
increased skin pigmentation, especially 
of the elbows, knees, knuckles, and 
gingivae. Serum Na+ was 121 meq/L and 
serum K+ was 5.2 meq/L. Serum cortisol 
was 193 nmol/L (normal, 28-662 nmol/ 
L) and did not increase after stimulation 
with adrenocorticotrophic hormone 
(ACTH). Urinary 17-hydroxysteroid ex- 
cretion was low. Plasma ACTH was 6300 
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Figure 1. Plasma immunoreactive gonadotropin patterns in response to pulsatile administra- 
tion of synthetic GnRH in case 1. Gonadotropin values are expressed as Iv/L of the second 
IRP-hMG standard. 
secretion before and after 5 days of in an increase of serum testosterone 
exogenous GnRH given intravenously from undetectable to 2.1 nmol/L, a poor 
every 2 h (0.025 pg./kg per dose). The response. Subsequently he received ther- 
results are depicted in Figure 2. Pulsatile apy with gradually increasing doses of 
administration of synthetic GnRH re- the long-acting testosterone ester, testos- 
sulted in an increase in FSH secretion, terone enanthate (up to 200 mg i.m. 
but no change in LH secretion. He then every 4 weeks), with induction of mas- 
received human chorionic gonadotropin culinization. At 20 years of age, his 
(hCG), 2000 U intramuscularly (i.m.> physical examination revealed Tanner 
every 3 days for 8 weeks, which resulted stage-3 penile development and pubic 
Figure 2. Plasma gonadotropin patterns and bioactive FSH (B-FSH) in response to pulsatile 
administration of synthetic G&I-I in case 2. Arrows denote administration of synthetic GnRH 
pulses. B-FSH was measured before and after these GnRH pulses (top panel). B-FSH values 
are expressed as ng/mL of the hFSH3 standard. Immunoreactive LH and FSH are presented in 
the bottom panel. 
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5r 




1 234 5 6 7 
Day 
hair. Testes were small, measuring 3 cm 
on the longer axis, and the scrotum was 
poorly developed. 
?? Case Presentation 3 
An infant boy presented at 2 weeks of age 
with frequent vomiting, weight loss, 
dehydration, and apathy. His case his- 
tory was presented before (Virdis et al. 
1983) and only a brief summary is 
outlined here. His brother died suddenly 
at the age of 2 months; an autopsy 
revealed interstitial pneumonia, but the 
adrenal glands were not evaluated. Birth 
weight of this infant (case 3) was 4300 g. 
Laboratory evaluation revealed hyperka- 
lemia and hyponatremia. Primary adre- 
nal insufficiency was diagnosed, based 
on low concentrations of urinary 17- 
hydroxysteroids and 17-ketosteroids, and 
plasma aldosterone, cortisol, and 17- 
hydroxyprogesterone, as well as unre- 
sponsiveness to ACTH stimulation. Ther- 
apy was started with hydrocortisone 
succinate and a mineralocorticoid (fludro- 
cortisone). He grew along the third 
percentile until 12 years of age, when his 
relative growth slowed further. Skeletal 
maturation had been 4’12 years at s8/~2 
years of age, and the delay in skeletal 
maturation increased progressively; at 
12’12 years of age, his bone age was 9’12 
years. Serum androgen concentrations 
[dehydroepiandrosterone (DORA), DHEA 
sulfate, androstenedione, and testoster- 
one] were measured periodically begin- 
ning at 12 years of age and were low. At 
145/~2 years, slight development of pubic 
hair growth was noted, but no further 
pubertal changes developed. Between 
14’/2 and 16 years of age, he had a slight 
increase in serum testosterone, but serum 
testosterone fell to within the prepuber- 
tal range by age 17 years. Results of a 
synthetic GnRH stimulation test (2.5 
pg/kg i.v.) suggested gonadotropin defi- 
ciency, as LH and FSH concentrations 
did not increase. He was admitted to the 
Clinical Research Center for a S-day 
GnRH stimulation protocol during which 
intravenous bolus injections of GnRH 
(0.025 @kg per dose) were given every 2 
h. His plasma gonadotropin responses 
are depicted in Figure 3. Plasma im- 
munoreactive and bioactive FSH con- 
centrations increased, but LH concentra- 
tions as well as LH a subunit (data not 
shown) remained low. At 18 years of age, 
treatment with a depot preparation of 
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Figure 3. Plasma immunoreactive gonadotropin patterns in response to pulsatile synthetic 
GnRH administration in case 3. 
testosterone esters was begun, and secon- 
dary sex characteristics developed over 
the ensuing months. 
0 Discussion 
Idiopathic congenital adrenal hypopla- 
sia is a rare disorder with an overall 
estimated frequency of 1:12,500 live 
births (Kelch et al. 1984). Two distinct 
forms have been identified, based on the 
histologic appearance of the adrenal 
glands. The miniature adult form, also 
called anencephalic or secondary form, 
is characterized by small adrenal glands 
with normal architecture. There is a 
welldefined permanent zone and a greatly 
reduced fetal zone. This form is believed 
to be secondary to ACTH deficiency, 
such as seen in anencephalic infants, 
infants of mothers who received therapy 
with glucocorticoids during pregnancy, 
or infants with congenital anomalies of 
the hypothalamus or pituitary gland. 
This secondary form is usually sporadic, 
although few cases of autosomal re- 
cessive inheritance have been reported 
(Kelch et al. 1984; Prader et al. 1975); the 
observed association of achalasia and 
adrenal hypoplasia in a subset of familial 
cases suggests that autosomal recessive 
congenital adrenal hypoplasia may be 
heterogeneous (Allgrove et al. 1978). 
The primary, or cytomegalic, form is 
characterized by an absence of the per- 
manent zone of the adrenal cortex; the 
cytomegalic cells are larger than normal 
fetal adrenal cells and have nuclear 
inclusions due to cytoplasmic invagina- 
tions. The primary form of congenital 
adrenal hypoplasia is an X-linked disor- 
der usually manifesting as adrenal insuf- 
ficiency early in infancy, with low serum 
concentrations of glucocorticoids, miner- 
alocorticoids, and androgens. Failure to 
respond to ACTH stimulation is char- 
acteristic. As illustrated by all three case 
presentations, hypogonadotropic hy- 
pogonadism is noted at the expected 
time of pubertal maturation (Prader et 
al. 1975; Virdis et al. 1983; Hay et al. 
1981; Kelly et al. 1977; Golden et al. 
1977; Lippe and Golden 1978; Petersen 
et al. 1982). 
Clinical signs and symptoms of infants 
with adrenal hypoplasia include poor 
feeding, failure to gain weight, hyperpig- 
mentation, vomiting, diarrhea, vascular 
collapse, and sudden death. Dehydration, 
hyponatremia, hyperkalemia, acidosis, 
and hypoglycemia are common biochem- 
ical findings characteristic of combined 
gluco- and mineralocorticoid deficiency. 
These signs and symptoms are indistin- 
guishable from those seen in male in- 
fants with the salt-wasting form of congeni- 
tal adrenal hyperplasia due to 2 l- 
hydroxylase deficiency. A clue for differ- 
entiation between these two possible 
diagnoses in a male infant is the size of 
the genitalia. In infants with 21-hydrox- 
ylase deficiency, the testicles are normal 
in size and the phallus may be larger than 
normal owing to elevated plasma andro- 
gen concentrations. In contrast, the tes- 
tes and phallus are usually small in 
infants who have adrenal hypoplasia 
(Kelch et al. 1984). With prompt diagno- 
sis and replacement therapy, survival has 
increased greatly (Kelch et al. 1984; 
Viidis et al. 1983). Although the majority 
of patients present in infancy, some 
patients similar to case 2 do not present 
with classic signs and symptoms of adre- 
nal insufficiency until the later childhood 
years (Hay et al. 198 1, case 2; Kelly et al. 
1977; Golden et al. 1977). 
In a male infant, a presumptive diag- 
nosis of congenital adrenal hypoplasia 
may be reached by determination of 
serum concentrations of cortisol, aldos- 
terone, 17-hydroxyprogesterone, 17- 
hydroxypregnenolone, and DHEA and 
its sulfate, all of which are low. Plasma 
ACTH concentrations are increased. 
Demonstration of failure to increase 
serum concentrations of the above- 
mentioned steroids following administra- 
tion of ACTH strongly supports the 
diagnosis (Kelch et al. 1984; Kelly et al. 
1977; Petersenet al. 1982). Distinguishing 
patients with congenital adrenal hy- 
poplasia from those with hereditary ACTH 
unresponsiveness, although sometimes 
difficult, is usually made clinically, as 
the latter patients do not have significant 
mineralocorticoid deficiency nor are they 
gonadotropin deficient (Kelch et al. 1972). 
Replacement therapy with hydro- 
cortisone succinate, fludrocortisone, and 
salt (NaCl) should be initiated promptly 
and monitored carefully (Kelch et al. 
1984; Hughes 1988). Careful attention to 
growth velocity and rate of skeletal 
maturation is essential since, unlike the 
2 1 -hydroxylase-deficiency form of con- 
genital adrenal hyperplasia, there is no 
useful biochemical marker for adequacy 
of treatment of patients who have con- 
genital adrenal hypoplasia. 
As gonadotropin deficiency is com- 
monly associated with the primary form 
of adrenal hypoplasia, the patients must 
be followed closely for physical signs of 
pubertal maturation (Kelch et al. 1984; 
Petersen et al. 1982; Zachman et al. 
1980). When a patient with primary 
adrenal hypoplasia shows no signs of 
sexual maturation by 13-14 years of age, 
hypogonadotropic hypogonadism 
should be suspected. Low serum con- 
centrations of LH, FSH, and testosterone 
are usually found, and the responses of 
serum gonadotropin concentrations to a 
single GnRH bolus are usually low 
(Dunkel et al. 1985). A stimulation test 
with hCG, performed by administration 
of hCG 2000 U i.m. twice a week for 4-6 
weeks, and determination of serum tes- 
tosterone concentrations before and after 
the hCG therapy are recommended to 
evaluate testicular function before ther- 
apy with androgens is started (Dunkel et 
al. 1985). The majority of reported pa- 
tients had normal testicular responses to 
hCG (Kelch et al. 1984; Virdis et al. 1983, 
case 1; Hay et al. 1981; Kelly et al. 1977; 
Golden et al. 1977; Lippe and Golden 
1978; Petersen et al. 1982; Zachman et 
al. 1980; Gordon et al. 1984; Kikuchi et 
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al. 1987; Bovet et al. 1988; Kruse et al. 
1984; Partsch and Sippell 1989) though 
some patients had suboptimal responses 
(case 3; Virdis et al. 1983, case 2; Hay et 
al. 1981, case 1). We prefer to use a 
long-acting testosterone ester rather than 
hCG to achieve masculinization because 
of lower cost and lower frequency of 
injections. Initially, we start with 50-75 
mg of testosterone enanthate every 4 
weeks, and gradually increase the dose 
and frequency to 200 mg every 3 weeks 
over a 2- to 3-year period. 
In an attempt to explain the endo- 
crinologic basis of this disorder, Golden 
and colleagues (1977) proposed that a 
prenatal delay in the development of 
hypothalamic function might lead to the 
absence of ACTH during the critical 
period of adrenal development and also 
to permanent gonadotropin deficiency. 
There is little evidence to support this 
theory, however, and it seems unlikely 
that ACTH deficiency is involved in the 
pathogenesis as ACTH secretion is nor- 
mal or increased in patients with pri- 
mary adrenal hypoplasia. Also, this the- 
ory does not explain the finding of 
patients who have a delayed onset such 
as in case 3 and others (Hay et al. 1981; 
Kelly et al. 1977) who, based on clinical 
data, were presumed to have had normal 
function of the adrenal gland until the 
childhood years. Moreover, normal adre- 
nal function was documented by deter- 
mination of normal urinary excretion of 
adrenocorticosteroids in a patient who 
had a positive family history and who 
developed adrenal insufficiency at the 
age of 10 years (Golden et al. 1977; Lippe 
and Golden 1978). Similarly, Sills and 
colleagues (1983) reported a case of a 
male infant who demonstrated a progres- 
sive decline in adrenal function: at 2 
months of age, he had a normal cortisol 
response to ACTH, but his adrenal func- 
tion declined and, by 3 years of age, he 
had no response to ACTH. 
Whether the hypogonadotropic hy- 
pogonadism in patients who have con- 
genital adrenal hypoplasia is the result of 
pituitary or hypothalamic dysfunction 
has not been settled. Initial reports of the 
association of congenital adrenal hy- 
poplasia with isolated gonadotropin de- 
ficiency documented poor gonadotropin 
responses to a single dose of synthetic 
GnRH in the majority of the patients 
(Kelch et al. 1984; Prader et al. 1975; 
Virdis et al. 1983; Hay et al. 1981; Kelly 
et al. 1977; Golden et al. 1977), but not 
all (Petersen et al. 1982). This did not 
differentiate primary pituitary from 
hypothalamic dysfunction, as most pa- 
tients who have isolated gonadotropin 
deficiency, due to GnRH deficiency, as 
well as patients who have primary pitui- 
tary dysfunction, respond poorly or not 
at all to a single dose of synthetic GnRH 
(Dunkel et al. 1985). 
To try to differentiate between hy- 
pothalamic and pituitary gland dys- 
function, more prolonged administration 
of GnRH is required (Kelch et al. 1984; 
Barkan et al. 1985). Several recent re- 
ports have suggested pituitary gland 
dysfunction as the primary defect, based 
upon lack of gonadotropin responses to 
prolonged, pulsatile stimulation with 
synthetic G&I-I (Gordon et al. 1984; 
Kikuchi et al. 1987; Bovet et al. 1988). 
Gordon and associates (1984) described 
striking differences in responses to GnRH 
between a patient with Kallman’s syn- 
drome, whose LH and FSH rose to 
within the normal range after 1 week of 
therapy, and a patient with congenital 
adrenal hypoplasia in whom only mini- 
mal increases of LH and FSH were found 
after 16 weeks of therapy. Serum testos- 
terone concentrations increased in the 
patient with Kallman’s syndrome, but 
not in the patient with adrenal hypopla- 
sia. Similar observations of failure to 
produce pubertal LH and FSH secretion 
in patients with X-linked adrenal hy- 
poplasia after prolonged treatment with 
pulsatile G&I-I have been reported by 
others (Kikuchi et al. 1987; Bovet et al. 
1988). The possibility of primary pitui- 
tary dysfunction is further supported by 
the finding of Marsden and Zakkhour 
( 1978), who reported cytomegalic changes 
in the pituitary gland of an infant who 
died of congenital adrenal hypoplasia. 
In contrast, Partsch and Sippell ( 1989) 
reported successful induction of puber- 
tal concentrations of LH, FSH, and 
testosterone 2-3 months after initiation 
of therapy with pulsatile synthetic GnRH, 
suggesting hypothalamic dysfunction as 
the principal defect in their patient with 
congenital X-linked adrenal hypoplasia. 
At least initially, patients with severe 
endogenous GnRH deficiency respond to 
exogenous GnRH with the preferential 
secretion of FSH (Barkan et al. 1985). 
This may be important, as the patients 
studied by Kikuchi et al. (1987) had 
increased serum FSH concentrations and 
normalization of FSH responses to syn- 
thetic GnRH although serum LH 
hyporesponsiveness persisted. Thus, the 
increases in serum FSH noted in our 
cases (Figures l-3), as well as others, 
support the possibility of a primary 
hypothalamic abnormality (Kruse et al. 
1984). Finally, in case 2, serum bioactive 
FSH responses to synthetic GnRH in- 
creased after pulsatile GnIU-I therapy 
similar to findings in patients with idio- 
pathic hypogonadotropic hypogonadism 
(Padmanabhan et al. 1988). 
Differences in gonadotropin responses 
of patients with congenital adrenal hy- 
poplasia to the prolonged administra- 
tion of synthetic GnRH might be attrib- 
uted to differences in the treatment 
protocols, but this seems unlikely, since 
the frequency of pulsatile injections var- 
ied only between 90 and 120 min and the 
dosage range was 0.05-0.2 @kg per 
dose (Bovet et al. 1988; Gordon et al. 
1984; Kikuchi et al. 1987; Kruse et al. 
1984; Partsch and Sippelll989). Altema- 
tively, since histologic or precise genetic 
confirmation of the diagnosis has been 
unavailable in patients who have re- 
ceived pulsatile GnRH, the syndrome of 
congenital adrenal hypoplasia with iso- ’ 
lated gonadotropin deficiency may be 
genetically heterogeneous. Thus far, no 
more than one affected individual from 
an involved family has received pro- 
longed stimulation with synthetic GnRH. 
It will be important to determine whether 
G&I-I responsiveness differs among af- 
fected boys within a kindred and whether 
different families have different genetic 
abnormalities. 
Appropriate genetic counseling is an 
important component of the overall man- 
agement of families with an affected 
child. To assist in differentiating be- 
tween the autosomal recessive and the 
X-linked forms of congenital adrenal 
hypoplasia, a detailed pedigree of the 
proband’s family should be obtained, 
126 01991, Elsevier Science Publishing Co., 1043-2760/91/$2.00 TEM Vol. 2, No. 4, 1991 
with particular attention to the previous 
occurrence of neonatal or unexplained 
deaths, similarly affected individuals 
within the maternal lineage, and the 
possibility of consanguinity. Since adre- 
nal insufficiency can precede neurologic 
symptoms by months to years in individ- 
uals with X-linked adrenoleukodystrophy 
(AID), a distinctly different X-linked 
disease mapped to Xq28 (Mandel et al. 
1989) pertinent laboratory assays, such 
as serum long-chain fatty-acid quantifi- 
cation (elevated in AID), may be indi- 
cated to assist in making an accurate 
diagnosis. In families with a documented 
affected male infant with X-linked adre- 
nal hypoplasia, the recurrence risk for a 
subsequent male infant may be as high 
as SO%, with a similar risk for a female 
sibling of being a gene carrier. 
Hammond et al. (1985) suggested that 
the locus for X-linked congenital adrenal 
hypoplasia and that for glycerol kinase 
were located on the short arm of the X 
chromosome within the region Xpl1.2- 
p2 1, based on the findings of an intersti- 
tial Xp deletion with breakpoints at 
Xpll.2 and Xp2 1 in a phenotypically 
normal mother of a male infant who died 
at 36 h of cytomegalic adrenal hypopla- 
sia with glyceroluria (indicating glycerol 
kinase deficiency) and omithine tran- 
scarbamoyltransferase deficiency. The 
molecular genetic analyses of multiple 
unrelated affected males with observed 
cytologic and submicroscopic interstitial 
deletions have localized the X-linked 
congenital adrenal hypoplasia locus to 
region Xp2 1.3-p2 1.2 (Bartley et al. 1986; 
Francke et al. 1987; Mandel et al. 1989) 
between two anonymous DNA sequences, 
DXS67 and DXS268, with a gene order 
of Xpter-DSX67-AH-GK-DXS268-DMD- 
OTC-Xcen (Xp telomere, Xpter; adrenal 
hypoplasia, AH: glycerol kinase, GK; 
Duchenne muscular dystrophy, DMD; 
ornithine transcarbamoyltransferase, 
OTC; and X centromere, Xcen) (Goone- 
wardena et al. 1989). These studies 
indicate that it may be feasible to use 
polymorphic DNA markers closely 
linked to the adrenal hypoplasia locus to 
provide prenatal diagnostic studies to 
families with a previously affected mem- 
ber. 
Not infrequently, patients with X- 
linked adrenal hypoplasia have been 
found to be affected with additional 
X-linked diseases such as Duchenne 
muscular dystrophy, glycerol kinase de- 
ficiency, omithine transcarbamoyltrans- 
ferase deficiency, and mental retardation 
as a consequence of having an interstitial 
deletion within Xp2 1 disrupting a num- 
ber of neighboring, or contiguous, ge- 
netic loci (Hammond et al. 1985; Bartley 
et al. 1986; Francke et al. 1987). These 
patients present with a variety of clinical 
problems depending on which contigu- 
ous genes have been disrupted; the vari- 
ous clinical syndromes resulting from 
different overlapping deletions have been 
referred to as contiguous deletion syn- 
dromes (Schmickell986; Emanuel 1988). 
Because X-linked adrenal hypoplasia is 
not uncommonly a consequence of an 
X-chromosome deletion, affected patients 
should be evaluated for clinical signs of 
other diseases mapped to Xp21 and, 
when appropriate, diagnostic studies, 
including a karyotype and urine organic 
acids, should be obtained. 
In a male infant from an affected 
kindred, the finding of normal results of 
adrenal function at birth does not rule 
out the possibility of X-linked adrenal 
hypoplasia, as onset of symptoms may 
be delayed in some patients (case 1; Hay 
et al. 1981; Kelly et al. 1977; Golden et al. 
1977; Sills et al. 1983), and thus careful 
follow-up is indicated. 
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